Aurora Cannabis Inc. filings document its U.S. reporting as a Canadian foreign private issuer and the formal disclosure record for its medical cannabis operations. Recent Form 6-K reports furnish news releases, material change reports, sales agreements and offering documents tied to product launches, financial results, acquisitions, governance matters and capital-structure activity.
The filings include disclosure for an at-the-market common-share program under shelf registration documents, material change reports on corporate transactions, and exhibits incorporated by reference into Form F-10 and Form S-8 registration statements. They also record Aurora's operating updates across regulated cannabis markets, GMP-certified manufacturing network, shareholder voting matters and executive-level governance disclosures.
Aurora Cannabis Inc. reports significant progress in its research on powdery mildew-resistant cannabis, known as PM2, in this Form 6-K. The company has moved from lab work to production trials of cultivars with verified PM2 resistance at its Aurora Ridge facility, using controlled infection tests to confirm disease resistance while maintaining high-quality traits for patients and consumers.
Aurora has presented this work at several scientific conferences and notes that the PM2 marker technology, developed at its Aurora Coast R&D center with academic and funding partners, is patent pending in Canada, the United States, Europe, Australia, New Zealand and Israel. If production trials succeed, Aurora plans to commercialize powdery mildew-resistant cultivars later this year, aiming to protect plant health, reduce operational costs and improve product quality across its global medical cannabis portfolio.